These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16640098)

  • 1. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.
    Bezemer D; de Ronde A; Prins M; Porter K; Gifford R; Pillay D; Masquelier B; Fleury H; Dabis F; Back N; Jurriaans S; van der Hoek L;
    Antivir Ther; 2006; 11(2):173-8. PubMed ID: 16640098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
    Kühnert D; Kouyos R; Shirreff G; Pečerska J; Scherrer AU; Böni J; Yerly S; Klimkait T; Aubert V; Günthard HF; Stadler T; Bonhoeffer S;
    PLoS Pathog; 2018 Feb; 14(2):e1006895. PubMed ID: 29462208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
    Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
    de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
    Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
    Paintsil E; Margolis A; Collins JA; Alexander L
    J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M; Clotet B; Martínez MA
    J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
    Theys K; Deforche K; Vercauteren J; Libin P; van de Vijver DA; Albert J; Asjö B; Balotta C; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Hamouda O; Horban A; Korn K; Kostrikis LG; Kücherer C; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stockl E; Riva C; Ruiz L; Liitsola K; Schmit JC; Schuurman R; Sönnerborg A; Stanekova D; Stanojevic M; Struck D; Van Laethem K; Wensing AM; Boucher CA; Vandamme AM;
    Retrovirology; 2012 Oct; 9():81. PubMed ID: 23031662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
    Harrison L; Castro H; Cane P; Pillay D; Booth C; Phillips A; Geretti AM; Dunn D;
    AIDS; 2010 Jul; 24(12):1917-22. PubMed ID: 20588166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.